contractpharmaDecember 10, 2020
Tag: GenScript ProBio , Initium Therapeutics , antibody
On December 7, 2020, GenScript ProBio and Initium Therapeutics announced that Initium Therapeutics has launched a single B-cell based antibody development platform through collaboration with GenScript ProBio.
Initium Therapeutics is a US biotechnology company, a spin-off from South Korean biotech company Tiumbio, seeking antibody-based therapeutics for patients who are suffering from unaddressed incurable and rare diseases.
Goals of the Partnership
The strategic collaboration between the two companies will allow Initium Therapeutics to expand their antibody drug pipeline using GenScript ProBio's ultra-rapid, high-efficient Berkeley Lights Beacon platform. Furthermore, their partnership will potentially be extended to GenScript ProBio's cutting edge therapeutic antibody development platforms, including bispecific antibody platform, human antibody transgenic mouse and/or downstream therapeutic antibody development and manufacturing processes. Through this partnership, Initium Therapeutics expects to significantly accelerate their therapeutic antibody pipeline development.
"We are very pleased to announce that through the strategic collaboration with GenScript ProBio, we will expand our therapeutic antibody pipeline in fibrosis, immuno-oncology and hemophilia," commented Dr. Huntaek Kim, CEO of Initium Therapeutics/TiumBio. "Initium Therapeutics was established to develop innovative antibody-based therapeutics focusing on unaddressed rare diseases. Our deep scientific and drug development expertise have allowed us to recognize new therapeutic targets in fibrosis, immuno-oncology and hemophilia, and I believe the partnership with GenScript ProBio will strengthen our therapeutic antibody platform and expand our antibody pipeline in more rapid and highly efficient ways."
"We are very glad to cooperate with Initium Therapeutics and help them expand their therapeutic antibody pipeline in fibrosis, immuno-oncology and hemophilia by utilizing GenScript ProBio's Berkeley Lights Beacon platform," said Dr. Brian Min, CEO of GenScript ProBio. "Our Single B cell screening platform dramatically expedites and enables unparalleled B cell diversity. We will continue fueling Initium's first-rate research capabilities and look forward to further collaboration to bring diverse treatment options to patients in rare diseases," he added.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: